Abstract
Current nanostructured biomaterials-based drug delivery vehicles for bone regeneration applications often show suboptimal cellular uptake and inferior drug loading. To overcome these challenges, we have developed a biomimetic cell-derived nanoparticle (CDN) loaded with the Food and Drug Administration-approved small-molecule therapeutic Dexamethasone, to induce osteogenic differentiation in human adipose-derived stem cells. The drug-loaded CDNs were cytocompatible, maintained hydrodynamic stability with uniform spherical shape and size, and exhibited high-percentage drug loading along with rapid cellular uptake and stem cell differentiation. These results demonstrate for the first time the preparation of Dexamethasone-loaded CDNs capable of directing stem cell fate for advanced bone regeneration applications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
